Chemotherapy for advanced urothelial cancer: end of the beginning?
Mené en Espagne sur 88 patients atteints d'un carcinome urothélial de stade avancé, cet essai de phase II évalue l'efficacité, du point de vue de la survie sans progression, de la vinflunine en traitement d'entretien après une chimiothérapie de première ligne
The effectiveness of first-line platinum-based chemotherapy to treat advanced urothelial cancer in the perioperative and front-line metastatic settings is an established management strategy supported by level 1 evidence.1,2 Over the past 25 years, many chemotherapeutic agents have been tested as salvage therapies without establishing data-driven standards of care,3 except, perhaps, vinflunine. When compared with best supportive care in a randomised study of patients with progression of transitional cell carcinoma of urothelial tract after platinum-based chemotherapy, vinflunine was associated with improved progression-free survival, disease control, and overall response.
The Lancet Oncology , commentaire, 2016